I am the driving force behind Import Tourism with a vision to broaden the company’s readership throughout 2016. I am an editor and reporter of “Technology” category.
Address: 3194 Flynn Street, Garfield Heights, OH 44125, USA
Phone: (+1) 440-829-5759
Latest posts by Raymond Young (see all)
- Softwares maintain the Legacy even after Emergence of New Technologies - February 17, 2020
- Seattle Smartphone Users Take Electronic Balloting To a Level Up - February 12, 2020
- Samsung’s Foldable Phone To Be Unveiled Soon - February 12, 2020
SANTA CLARA, Calif., August 21, 2019 – Shares of Agilent Technologies Inc. (NYSE: A) showed the bearish trend with a lower momentum of -0.88% to $71.12. The company traded total volume of 2.165M shares as contrast to its average volume of 2.72M shares. The company has a market value of $22.55B and about 317.00M shares outstanding.
Agilent Technologies, Inc. (NYSE:A) recently reported revenue of $1.24B for the second quarter ended April 30, 2019, up 3 percent year-over-year (up 4 percent on a core basis).
On a GAAP basis, second-quarter net income was $182.0M or $0.57 per share. This compares with $205.0M and $0.63 per share in the second quarter of 2018. Non-GAAP net income was $228.0M or $0.71 per share during the quarter, contrast with $212.0M and $0.65 per share during the second quarter a year ago.
Life Sciences and Applied Markets Group
Second-quarter revenue of $529.0M from Agilent’s Life Sciences and Applied Markets Group (LSAG) was down 1 percent year over year (down 1 percent on a core basis). Demand in the environmental and forensics markets was strong, offset by weakness in the pharma and food markets. LSAG’s operating margin for the quarter was 20.3 percent.
Agilent CrossLab Group
Second-quarter revenue of $455.0M from the Agilent CrossLab Group (ACG) grew 7 percent year over year (up 9 percent on a core basis). Growth was broad-based across all regions, led by China. ACG’s operating margin for the quarter was 25.2 percent.
Diagnostics and Genomics Group
Second-quarter revenue of $254.0M from Agilent’s Diagnostics and Genomics Group (DGG) grew 5 percent year over year (up 6 percent on a core basis). Strength in the company’s pathology-related businesses and NASD led the group’s results. DGG’s operating margin for the quarter was 19.3 percent.
Third-Quarter and Full-Year Outlook:
Agilent anticipates third-quarter 2019 revenue in the range of $1.225B to $1.245B. Third-quarter 2019 non-GAAP earnings are expected to be in the range of $0.71 to $0.73 per share.
For fiscal year 2019, the company is revising its full-year revenue guidance to a range of $5.085B to $5.125B while maintaining non-GAAP earnings guidance in the range of $3.03 to $3.07 per share.
The Company offered net profit margin of 22.30% while its gross profit margin was 54.80%. ROE was recorded as 23.20% while beta factor was 1.42. The stock, as of recent close, has shown the weekly upbeat performance of 5.14% which was maintained at 5.43% in this year.